Format

Send to

Choose Destination
J Alzheimers Dis. 2014;42(1):1-68. doi: 10.3233/JAD-140402.

Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.

Author information

1
AC Immune SA, EPFL, Lausanne, Switzerland.

Abstract

Scientists working in the field of Alzheimer's disease and, in particular, cognitive enhancers are very productive. The review on Drugs interacting with Enzymes was accepted in August 2012. However, this field is very dynamic. New potential targets for the treatment of Alzheimer's disease were identified. This update describes drugs interacting with 60 enzymes versus 43 enzymes in the first paper. Some compounds progressed in their development, while many others were discontinued. The present review covers the evolution of research in this field through April 2014.

KEYWORDS:

Alzheimer's disease; cognitive enhancers; donepezil; enzymes; galantamine; memory; rivastigmine

PMID:
24903780
DOI:
10.3233/JAD-140402
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center